Evaluation of fluocinolone acetonide 0.19 mg intravitreal implant in the management of birdshot retinochoroiditis [PDF]
, 2020 Purpose: To report treatment outcomes and efficacy of the fluocinolone acetonide 0.19 mg intravitreal implant (Iluvien) in controlling retinal and choroidal inflammation in 11 patients with birdshot retinochoroiditis.
Ajamil-Rodanes, S +5 more
core
Corticosteroidi per via Intravitreale per il Trattamento Dell'edema Maculare: Revisione e Valutazione Della Qualità Dell'evidenza: [PDF]
, 2017 Intravitreal corticosteroids for the treatment of macular edema: review and assessment of quality of the evidenceIntroductionTreatment options for macular edema include intravitreal corticosteroids.
Luz Irene Urbina +4 more
core +2 more sources
ILUVIEN—A New Approach to the Treatment of Diabetic Macula Edema
US Ophthalmic Review, 2015 The antivascular endothelial growth factor (VEGF) ranibizumab (Lucentis) and aflibercept (EYLEA) and the intraocular corticosteroids dexamethasone (Ozurdex) and fluocinolone acetonide (ILUVIEN) are approved for treating diabetic macular edema (DME) in the US.
Richard Parrish, Pravin U Dugel
openaire +1 more source
Anti‐VEGF Therapy and the Retina: An Update
Journal of Ophthalmology, Volume 2015, Issue 1, 2015., 2015 Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring.
Vikas Tah +8 more
wiley +1 more source
Manejo del edema macular diabético refractario con Ozurdex®. Respuesta clínica [PDF]
, 2017 El edema macular diabético (EMD) constituye una entidad de gran repercusión socio-sanitaria. Tiene una prevalencia elevada y en aumento dentro de los pacientes con retinopatía diabética (RD), suponiendo una importante sobrecarga asistencial en los ...
Fernández Gutiérrez, Javier
core
Ophtalmologie. Rétinopathie diabétique: nouvelles possibilités thérapeutiques [Diabetic retinopathy: new therapeutic possibilities]. [PDF]
, 2015 La rétinopathie diabétique touche un nombre croissant de personnes, soit quatre millions en Europe, ce chiffre va probablement doubler d'ici 2030. Si l'on considère que 25-30% de ces patients sont atteints de rétinopathie diabétique, un dépistage et un ...
Behar-Cohen, F., Guex-Crosier, Y.
core
Letter to the editor: dexamethasone intravitreal implant in the treatment of diabetic macular edema
Clinical Ophthalmology, 2015 John Hall Alimera Sciences Ltd., Aldershot, Hampshire, UK I read “Dexamethasone intravitreal implant in the treatment of diabetic macular edema” published July 2015 by Dugel et al.1This article is very interesting in terms of providing an
Hall J
doaj
Journal of Medical Case Reports, 2019 Background In this report, we present the results of a severe case of Sjögren’s syndrome-related keratopathy after fluocinolone acetonide 190-μg intravitreal implant (Iluvien®; Alimera Sciences Inc.) therapy.
Joanna Wasielica-Poslednik +2 more
doaj +1 more source
Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes [PDF]
, 2019 Purpose: The aim of this study was to evaluate the long-term real-world effectiveness of FAc and DEX implants in vitrectomized DME eyes in a real-world setting.
Coelho, João +4 more
core +1 more source